Document:

Employee Agreement dated February 23, 2005

 Exhibit 10.12 
  
 EMPLOYMENT AGREEMENT 
  
 This Employment Agreement (“Agreement”), made and effective this 23rd day of February, 2005, by and between XOMA (US) LLC (“XOMA” or
the “Company”), a Delaware limited liability company with its principal office at 2910 Seventh Street, Berkeley, California, and Christopher J. Margolin (“Executive”), an individual residing at 210 Willowbrook Drive, Portola
Valley, California. 
  
 WHEREAS, the Company wishes to enter into
this Agreement to assure the Company of the continued services of Executive; and 
  
 WHEREAS, Executive is willing to enter into this Agreement and to continue to serve in the employ of the Company upon the terms and conditions hereinafter provided; 
  
 NOW, THEREFORE, in consideration of the mutual covenants herein contained,
the parties hereto hereby agree as follows: 
  
 1.
Employment. The Company agrees to continue to employ Executive, and Executive agrees to continue to be employed by the Company, for the period referred to in Section 3 hereof and upon the other terms and conditions herein provided.

  
 2. Position and Responsibilities. The Company agrees
to employ Executive in the position of Vice President, General Counsel and Secretary, and Executive agrees to serve as Vice President, General Counsel and Secretary, for the term and on the conditions hereinafter set forth. Executive agrees to
perform such services not inconsistent with his position as shall from time to time be assigned to him by the Chairman of the Board, President and Chief Executive Officer of the Company (the “Chairman”). 
  
 3. Term and Duties. 
  
   (a) Term of Employment. This Agreement
shall become effective and the term of employment pursuant to this Agreement shall commence on February 23, 2005 and will continue until February 22, 2006, and will be automatically extended (without further action by the parties) for one year
thereafter and again on each subsequent anniversary thereof unless terminated by mutual written consent of Executive and the Company more than 90 days prior to the next scheduled expiration date or unless Executive’s employment is terminated by
the Company or he resigns from the Company’s employ as described herein. 
  
   (b) Duties. During the period of his employment hereunder Executive shall serve the Company as its Vice President, General Counsel and Secretary, and except for illnesses, vacation periods and
reasonable leaves of absence, Executive shall devote all of his business time, attention, skill and efforts to the faithful performance of his duties hereunder. So long as Executive is Vice President, General Counsel and Secretary of the Company, he
will discharge all duties incidental to such office and such further duties as may be reasonably assigned to him from time to time by the Chairman. 
  
 4. Compensation and Reimbursement of Expenses. 
  
   (a) Compensation. For all services rendered by Executive as Vice President, General Counsel and Secretary during his
employment under this Agreement, the Company shall pay Executive as compensation a base salary at a rate of not less than $290,000 per annum. All taxes and governmentally required withholding shall be deducted in conformity with applicable laws.

   (b) Reimbursement of Expenses. The Company shall pay or reimburse
Executive for all reasonable travel and other expenses incurred by Executive in performing his obligations under this Agreement in a manner consistent with past Company practice. The Company further agrees to furnish Executive with such assistance
and accommodations as shall be suitable to the character of Executive’s position with the Company, adequate for the performance of his duties and consistent with past Company practice. 
  
 5. Participation in Benefit Plans. The payments provided in Section 4
hereof are in addition to benefits Executive is entitled to under any group hospitalization, health, dental care, disability insurance, surety bond, death benefit plan, travel and/or accident insurance, other allowance and/or executive compensation
plan, including, without limitation, any senior staff incentive plan, capital accumulation and termination pay programs, restricted or non-restricted share purchase plan, share option plan, retirement income or pension plan or other present or
future group employee benefit plan or program of the Company for which key executives are or shall become eligible, and Executive shall be eligible to receive during the period of his employment under this Agreement, and during any subsequent
period(s) for which he shall be entitled to receive payment from the Company under paragraph 6(b) below, all benefits and emoluments for which key executives are eligible under every such plan or program to the extent permissible under the general
terms and provisions of such plans or programs and in accordance with the provisions thereof. 
  
 6. Payments to Executive Upon Termination of Employment. 
  
   (a) Termination. Upon the occurrence of an event of termination (as hereinafter defined) during the period of
Executive’s employment under this Agreement, the provisions of this paragraph 6(a) and paragraph 6(b) shall apply. As used in this Agreement, an “event of termination” shall mean and include any one or more of the following:

  
 (i) The termination by the Company of
Executive’s employment hereunder for any reason other than pursuant to paragraph 6(c); or 
  
 (ii) Executive’s resignation from the Company’s employ for Good Reason, upon not less than thirty (30) days’ prior written
notice. “Good Reason” means, without the Executive’s written consent, (A) the material diminution of any material duties or responsibilities of the Executive without the same being corrected within ten (10) days after being given
written notice thereof; (B) a material reduction in the Executive’s base salary; or (C) the Company giving written notice of its intention not to extend the term of this Agreement as provided in paragraph 3(a). 
  
   (b) Continuation of Salary and Other
Benefits. Upon the occurrence of an event of termination under paragraph 6(a), the Company (i) shall, subject to the provisions of Section 7 below, pay Executive, or in the event of his subsequent death, his beneficiary or beneficiaries of his
estate, as the case may be, as severance pay or liquidated damages, or both, semi-monthly for a period of nine (9) months following the event of termination (the “Severance Payment Period”), a sum equal to his current salary in effect at
the time of the event of termination, but in no case at a rate less than $290,000 per annum, (ii) shall continue to provide the other benefits referred to in Section 5 hereof until the end of the Severance Payment Period or until Executive becomes
employed elsewhere, whichever is earlier, and (iii) shall continue to provide the benefits provided for in paragraph 4(b) to the extent of expenses incurred but not reimbursed prior to the event of termination. Such payments shall commence on the
last day of the next regular pay period following the date of the event of termination, or, at the election of the Company, may be paid in one lump sum or in such other installments as may be mutually agreed between the Company and Executive or, in
the event of his subsequent death, his beneficiary or beneficiaries or legal representative, as the case may be. 
  

 -2- 

   (c) Other Termination of Employment. Notwithstanding paragraphs 6(a)
and (b) or any other provision of this Agreement to the contrary, if on or after the date of this Agreement and prior to the end of the term hereof: 
  
 (i) Executive has been convicted of any crime or offense constituting a felony under applicable law, including, without limitation, any
act of dishonesty such as embezzlement, theft or larceny; 
  
 (ii) Executive shall act or refrain from acting in respect of any of the duties and responsibilities which have been assigned to him in accordance with this Agreement and shall fail to desist from such action or
inaction within ten (10) days (or such longer period of time, not exceeding ninety (90) days, as Executive shall in good faith and the exercise of reasonable efforts require to desist from such action or inaction) after Executive’s receipt of
notice from the Company of such action or inaction and the Board of Directors determines that such action or inaction constituted gross negligence or a willful act of malfeasance or misfeasance of Executive in respect of such duties; or 

 
 (iii) Executive shall breach any material term of this
Agreement and shall fail to correct such breach within ten (10) days (or such longer period of time, not exceeding ninety (90) days, as Executive shall in good faith and the exercise of reasonable efforts require to cure such breach) after
Executive’s receipt of notice from the Company of such breach; 
  
 then, and in each such case, the Company shall have the right to give notice of termination of Employee’s services hereunder as of a date (not earlier than fourteen (14) days from such notice) to be specified in such notice and this
Agreement (other than the provisions of Section 7 hereof) shall terminate on such date. 
  
 7. Post-Termination Obligations. All payments and benefits to Executive under this Agreement shall be subject to Executive’s compliance with the following provisions during the term of his employment and
for the Severance Payment Period: 
  
   (a) Confidential Information and Competitive Conduct. Executive shall not, to the detriment of the Company, disclose or reveal to any unauthorized person any trade secret or other confidential information relating to the
Company or its affiliates or to any businesses operated by them, and Executive confirms that such information constitutes the exclusive property of the Company. Executive shall not otherwise act or conduct himself to the material detriment of the
Company or its affiliates, or in a manner which is inimical or contrary to the interests thereof, and shall not, directly or indirectly, engage in, enter the employ of or render any service to any person, firm or business in direct competition with
any part of the business being conducted by the Company; provided, however, that Executive’s ownership less than five percent (5%) of the outstanding stock of a corporation shall not be itself be deemed to constitute such competition.
Executive recognizes that the possible restrictions on his activities which may occur as a result of his performance of his obligations under this paragraph 7(a) are required for the reasonable protection of the Company and its investments. For
purposes hereof, “direct competition” means the pursuit of one or more of the same therapeutic or diagnostic indications utilizing a substantially similar scientific basis. 
  
   (b) Failure of Executive to Comply. If, for any reason other than death or disability,
Executive shall, without written consent of the Company, fail to comply with the provisions of paragraph 7(a) above, his rights to any future payments or other benefits hereunder shall terminate, and the Company’s obligations to make such
payments and provide such benefits shall cease. 
  

 -3- 

   (c) Remedies. Executive agrees that monetary damages would not be
adequate compensation for any loss incurred by the Company by reason of a breach of the provisions of this Section 7 and hereby agrees to waive the defense in any action for specific performance that a remedy at law would be adequate. 
  
 8. Effect of Prior Agreements. This Agreement contains the entire
understanding between the parties hereto and supersedes any prior employment agreements between the Company and Executive. 
  
 9. General Provisions. 
  
   (a) Binding Agreement. This Agreement shall be binding upon, and inure to the benefit of, Executive and the Company and
their respective permitted successors and assigns. 
  
   (b) Legal Expenses. In the event that Executive incurs legal expenses in contesting any provision of this Agreement and such contest results in a determination that the Company has breached any of its obligations
hereunder, Executive shall be reimbursed by the Company for such legal expenses. 
  
 10. Successors and Assigns. 
  
   (a) Assignment by the Company. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company and, unless clearly inapplicable, reference herein to the
Company shall be deemed to include its successors and assigns. 
  
   (b) Assignment by Executive. Executive may not assign this Agreement in whole or in part. 
  
 11. Modification and Waiver. 
  
   (a) Amendment of Agreement. This Agreement may not be modified or amended except by an instrument in writing signed by
the parties hereto. 
  
   (b)
Waiver. No term or condition of this Agreement shall be deemed to have been waived except by written instrument of the party charged with such waiver. No such written waiver shall be deemed a continuing waiver unless specifically stated
therein, and each such waiver shall operate only as to the specific term or condition waived. 
  
 12. Severability. In the event any provision of this Agreement or any part hereof is held invalid, such invalidity shall not affect any remaining part of such provision or any other provision. If any court
construes any provision of this Agreement to be illegal, void or unenforceable because of the duration or the area or matter covered thereby, such court shall reduce the duration, area or matter of such provision, and, in its reduced form, such
provision shall then be enforceable and shall be enforced. 
  
 13. Governing Law. This Agreement has been executed and delivered in the State of California, and its validity interpretation, performance, and enforcement shall be governed by the laws of said State. 
  

 -4- 

 IN WITNESS WHEREOF, XOMA has caused this Agreement to be executed by its duly authorized officer, and
Executive has signed this Agreement, all as of the day and year first above written. 
  

			
	XOMA (US) LLC
		
	By:	 	 /s/ JOHN L. CASTELLO

	 	 	 John L. Castello
 Chairman of the Board, President
and
 Chief Executive Officer

		
	 	 	 /s/ CHRISTOPHER J. MARGOLIN

	 	 	Christopher J. Margolin

  

 -5-Second Amended and Restated Collaboration Agreement

 Exhibit 10.26C 
  
 [*] indicates that a confidential portion of the text of this agreement has been omitted. The non-public information has been filed
separately with the Securities and Exchange Commission. 
  
 EXECUTION COPY 
  
 SECOND AMENDED AND RESTATED

 COLLABORATION AGREEMENT 
  
 THIS SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT (this “Agreement”) is executed as of January 12, 2005 (the
“Signature Date”) and is effective as of the 1st day of January 2005 (the “Effective Date”) by and between XOMA (US) LLC, a Delaware limited liability company having its principal place of business at 2910
Seventh Street, Berkeley, California 94710 (“XOMA”), and Genentech, Inc., a Delaware corporation having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”), each
on behalf of itself and its Affiliates. XOMA and Genentech are sometimes referred to herein individually as a “Party” and collectively as the “Parties,” and references to “XOMA” and “Genentech” shall include
their respective Affiliates. 
  
 RECITALS 
  
 1. Genentech licensed a monoclonal antibody (then known as MHM-24) to the
CD11a cell integrin on the surface of leucocytes under the terms of an Evaluation and License Agreement dated July 1, 1991 among Genentech, The Chancellor Masters and Scholars of the University of Oxford, Andrew J. McMichael and James E.K. Hildreth
(the “Oxford Agreement”). Genentech humanized such antibody and began its preclinical development, including the development of a pilot process for producing the antibody. 
  
 2. Genentech and XOMA’s predecessor in interest entered into that
certain Collaboration Agreement effective as of April 22, 1996, as amended by the Amendment thereto dated as of April 14, 1999 (the “Original Agreement”) and as further amended by the Amended and Restated Collaboration Agreement
dated March 31, 2003 (the “First Amended and Restated Agreement”). 
  
 3. XOMA Ltd. and Genentech entered into a Secured Note Agreement-Commercial Launch Loan on March 31, 2003, the full amount of the loan under which has been paid. 
  
 4. XOMA desires to terminate the U.S. profit and loss sharing arrangement
under the First Amended and Restated Agreement and be released from its obligations under the Note Agreement; in lieu of profit and loss sharing, XOMA desires to receive royalties in the U.S. The Parties are further revising the royalty structure
that would have applied had XOMA repaid to Genentech the entirety of the loan balance under the Note Agreement (defined below). 
  
 5. Genentech wishes to release XOMA Ltd. from its obligation under the Amended and Restated Convertible Secured Note Agreement - Development Loan between
Genentech and XOMA Ltd. dated March 31, 2003 (the “Note Agreement”) to repay to Genentech the balance of the principal loaned to XOMA Ltd. under the Note Agreement and any interest accrued on that principal. In addition, Genentech
wishes to release any security interest it may hold pursuant to the Security Agreement between Genentech and XOMA Ltd. dated March 31, 2003 (the “Security Agreement”). 
  
 6. Genentech and XOMA wish to amend and restate the First Amended and Restated Agreement on the terms set forth below.

 ARTICLE 1: DEFINITIONS 
  
 The following terms shall have the following meanings as used in this Agreement: 
  
 1.1 “Affiliate” means an entity that, directly or
indirectly, through one or more intermediaries, is controlled by XOMA or Genentech. As used herein, the term “control” will mean the direct or indirect ownership of fifty percent (50%) or more of the stock having the right to vote for
directors thereof or the ability to otherwise control the management of the corporation or other business entity. 
  
 1.2 “Aggregate Annual Net Sales” means aggregating the Net Sales amounts (occurring in the applicable calendar year) of each Licensed
Product sold in the applicable countries. For clarity, Net Sales amounts for different Licensed Products shall not be aggregated together and only Net Sales amounts of the same Licensed Product shall be aggregated together for the purpose of
calculating royalty tiers. 
  
 1.3 “Allocable
Overhead” means costs incurred by a Party or for its account that are attributable to a Party’s supervisory, services, occupancy costs, corporate bonus (to the extent not charged directly to department), and its payroll, information
systems, human relations or purchasing functions and which are allocated to company departments based on space occupied or headcount or other activity-based method. Allocable Overhead shall not include any costs attributable to general corporate
activities including, by way of example, executive management, investor relations, business development, legal affairs and finance. 
  
 1.4 “[*] Trial” is defined in Section 2.1. 
  
 1.5 “Anti-CD11a” means that certain monoclonal antibody now known as Efalizumab, and other constructs with minor modifications thereto
resulting from changes to the manufacturing process occurring after the transfer thereof from XOMA to Genentech, which recognizes the CD11a cell adhesion molecule on leucocytes, the full length sequences of the light and heavy chains of which are
set forth in Exhibit A attached hereto and incorporated herein. 
  
 1.6 “Clinical Trial” means any clinical trial in which Anti-CD11a (individually and not as a combination) is tested in human subjects, whether or not conducted in the United States, and whether such trial is a Phase I trial
designed to make an initial determination of safety, a Phase II trial designed to make a preliminary determination of efficacy and/or dose ranges, or a Phase III or pivotal trial designed to establish safety and efficacy for registration purposes,
or for any other purpose, or any combination of the foregoing. 
  
 1.7 “Combination Product Adjustment” means the following with respect to sales by Genentech or any sublicensee other than an Ex-U.S. Partner: in the event a Licensed Product is sold in the form of a combination product
containing one or more active ingredients in addition to a Licensed Product, Net Sales for such combination product will be adjusted by multiplying actual Net Sales of such combination product by the fraction A/(A + B), where A is the invoice price
of a Licensed Product, if sold separately, and B is the invoice price of any other active component or components in the combination, if sold separately. If, on a country-by-country basis, the other active component or components in the combination
are not sold separately in said country, Net Sales shall be calculated by multiplying actual Net Sales of such combination product by the fraction A/C, where A is the invoice price of the Product if sold separately and C is the invoice price of the
combination product. If, on a country-by-country basis, neither a Licensed Product nor the other active component or components of the combination product are sold separately in said country, Net Sales shall be determined by the Parties in good
faith. 
  
 1.8 “Commercially Reasonable and Diligent
Efforts” means those efforts consistent with the exercise of prudent scientific and business judgment, as applied to other pharmaceutical products of similar potential and market size by the Party in question. 
  
 1.9 “Control” means possession of the ability to grant a
license or sublicense, or to authorize access and use, as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 
  
 1.10 “Development Costs” means costs, including Allocable Overhead, arising from a Clinical Trial
(including transition of the [*] Trial). Development Costs shall include but are not limited to the cost of studies on the toxicological, pharmacokinetic, metabolic or clinical aspects of a Licensed Product conducted internally or by 
  

 -2- 

 individual investigators or consultants necessary for the purpose of obtaining and/or maintaining approval of a Licensed
Product in the Field by a government organization and costs for preparing, submitting, reviewing or developing data or information for the purpose of submission to a governmental authority to obtain and/or maintain approval of a Licensed Product in
the Field as well as costs of studies to add data to or expand package inserts and costs of scientific advisory boards. Development Costs shall include the cost of post-launch clinical studies in support of a Licensed Product in the Field.
Development Costs shall include expenses for compensation, benefits and travel and other employee-related expenses, as well as data management, statistical designs and studies, document preparation, and other expenses associated with the clinical
testing program. 
  
 1.11 “[*] Trial” is defined
in Section 2.1. 
  
 1.12 “Ex-U.S. Genentech
Partner” means an entity which has contractual rights pursuant to an agreement with Genentech to develop and commercialize Licensed Products in the Field in the Genentech Territory or any portion thereof. 
  
 1.13 “Field” means the use of Licensed Products for the
treatment, diagnosis or prevention of any human condition, disorder or disease. 
  
 1.14 “Genentech Know-How” means Information that (i) Genentech discloses to XOMA under this Agreement and (ii) is within the Control of Genentech. 
  
 1.15 “Genentech Patents” means Patents issued by or filed
with the United States Patent Office, owned by or Controlled by Genentech in whole or in part, that are necessary to make, use, sell, offer for sale or import a Licensed Product in the Field, including Patents owned jointly by the Parties as
provided hereunder. Notwithstanding the foregoing, but subject to Section 12.10, Genentech Patents shall not include any of the following: (i) the Itakura/Riggs Patents (which term is defined on Exhibit B, which is attached hereto and
incorporated herein), which patents Genentech represents are not required in connection with any manufacture or use of Anti-CD11a or a Licensed Product made in mammalian cells under this Agreement; (ii) the Cabilly Coexpression Patents (which term
is defined on Exhibit B, which is attached hereto and incorporated herein); and (iii) the Cabilly Chimera Patents (which term is defined on Exhibit B, which is attached hereto and incorporated herein). 
  
 1.16 “Genentech Territory” means worldwide (except for the
United States). 
  
 1.17 “Gross Sales” means the
gross amount invoiced by Genentech or its Affiliates or sublicensees for sales of a Licensed Product to Third Parties in the applicable country or countries. 
  
 1.18 “Information” means techniques and data relating to any Licensed Products, including, but not limited to, biological materials,
inventions, practices, methods, knowledge, know-how, skill, experience, test data including pharmacological, toxicological and clinical test data, analytical and quality control data, marketing, pricing, distribution, cost, sales, manufacturing,
patent data or descriptions. 
  
 1.19 “Investigational New
Drug Application” or “IND” means an “investigational new drug application,” as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, submitted for regulatory approval for
initiating clinical trials in the United States, or any equivalent foreign application, registration or certification. 
  
 1.20 “Licensed Product” or “Licensed Products” means a formulation for use in the Field containing Anti-CD11a.

  
 1.21 “Net Sales” means, with respect to sales
in the United States, Gross Sales less the sum of (a), (b) and (c) where (a) is a provision, determined under generally accepted accounting principles in the United States, for (i) trade, cash and quantity discounts or rebates (other than price
discounts granted at the time of invoicing and which are included in the determination of Gross Sales), (ii) credits or allowances given or made for rejection or 
  

 -3- 

 return of previously sold products or for retroactive price reductions (including Medicare and similar types of rebates),
(iii) taxes, duties or other governmental charges levied on or measured by the billing amount, as adjusted for rebates and refunds, (iv) charges for freight and insurance directly related to the distribution of Licensed Products (to the extent not
paid by the Third Party customer), and (v) credits or allowances given or made for wastage replacement, indigent patient and any other sales programs agreed to by the Parties, (b) is a periodic adjustment of the provision determined in (a) to
reflect amounts actually incurred for (i), (ii), (iii), (iv) and (v), and (c) is the Combination Product Adjustment as defined in this Agreement, if any. Provisions allowed in (a) and adjustments made in (b) and (c) will be reviewed by the
Parties’ financial representatives. 
  
 With respect to sales
by an Ex-U.S. Genentech Partner, Net Sales as used in the Agreement shall mean, as to each calendar quarter, the gross amount invoiced for all Licensed Products sold by an Ex-U.S. Genentech Partner, its Affiliates and sublicensees in arm’s
length transactions to Third Parties other than the Ex-U.S. Genentech Partner’s Affiliates or sublicensees in the Genentech Territory during such quarter, less (i) rebates and price reductions, retroactive or otherwise (including rebates
similar to Medicare or other government rebates), (ii) credits or allowances given or made for rejection or return of, and for uncollectible amounts on, previously sold Licensed Products, (iii) taxes, duties or other governmental charges levied on
or measured by the billing amount, as adjusted for rebates and refunds, (iv) charges for freight, postage and insurance directly related to the distribution of Licensed Products (to the extent not paid by the Third Party customer), (v) credits or
allowances given or made for wastage replacement, indigent patient and similar programs, to the extent actually deducted from the gross amount invoiced, and (vi) amounts debited on account of bad debts with respect to sales previously invoiced, all
of items (i) – (vi) above as adjusted periodically to represent actual results in accordance with International Accounting Standards (IAS). If applicable, amounts calculated pursuant to the foregoing paragraph (including subsections (i) –
(vi)), shall then be adjusted by the amount(s) defined in any agreement(s) between Genentech and any Ex-U.S. Genentech Partner(s) relating to the development of Anti-CD11a as the “Combination Product Adjustment” (which term may or may not
be the same as the term “Combination Product Adjustment” as defined in Section 1.7 of this Agreement), if applicable. 
  
 “Patent” means (i) valid and enforceable letters patent, including any extension, registration, confirmation, reissue, continuation,
division, continuation-in-part, re-examination or renewal thereof, and (ii) pending applications for letters patent. 
  
 “Regulatory Approval” means any approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations of
any federal, state or local regulatory agency, department, bureau or other governmental entity necessary for the manufacture and sale of Licensed Products in a regulatory jurisdiction. 
  
 “Third Party” means any entity other than XOMA or Genentech. 
  
 “United States” or “U.S.” shall mean the
United States of America, its territories and possessions. 
  
 “XOMA Know-How” means Information which (i) XOMA discloses to Genentech under this Agreement and (ii) is within the Control of XOMA. 
  

“XOMA Patents” means any and all Patents owned or Controlled in whole or in part by XOMA that are necessary to make, use, sell,
import, or offer for sale Licensed Product in the Field, including XOMA’s interest in any Patents owned jointly by the Parties as provided hereunder. 
  

 -4- 

 In addition, the following terms have the meanings given them in the corresponding Sections of this
Agreement: 
  

			
	 Term

	 	 Section

	Agreement	 	Introduction
	Approved Budget	 	3.9
	Article 11 Dispute	 	11.1
	CGL	 	10.3
	Confidential Information	 	5.1
	Effective Date	 	Introduction
	Filing Party	 	6.3(b)
	First Amended and Restated Agreement	 	Recitals
	Genentech	 	Introduction
	Genentech Inventions	 	6.1
	Initial U.S. Royalty Period	 	3.4(a)(1)
	Initial Ex-U.S. Royalty Period	 	3.4(a)(2)
	Joint Inventions	 	6.1
	Joint Patents	 	6.1
	Losses	 	10.1(a)
	Non-Anti-CD18 Anti-LFA1 Protein Product	 	3.4(b)(1)
	Note Agreement	 	Recitals
	Original Agreement	 	Recitals
	Oxford Agreement	 	Recitals
	Party/Parties	 	Introduction
	PL	 	10.3
	Relevant Information	 	8.1
	Security Agreement	 	Recitals
	Serious Adverse Event	 	8.5
	Signature Date	 	Introduction
	Term	 	9.1
	Unexpected Adverse Event	 	8.5
	XOMA	 	Introduction
	XOMA Inventions	 	6.1

  
 ARTICLE 2:
DEVELOPMENT AND MARKETING OF LICENSED PRODUCTS 
  
 2.1
Current Clinical Trials. 
  
 (a) [*] Trial. XOMA
and Genentech have been conducting a Clinical Trial of Raptiva® (or Efalizumab, a Licensed Product) for use in treating [*] (“[*] Trial”). After the Effective Date, XOMA will continue performing its activities for the [*] Trial,
in the same manner as XOMA has been performing those activities prior to the Effective Date, but in any event consistent with the existing protocols and other requirements for the [*] Trial. Reimbursement for Development Costs for the [*] Trial is
addressed in Section 3.9. 
  
 (b) [*] Trial. XOMA and
Genentech have been conducting preliminary work related to a Clinical Trial of Raptiva® (Efalizumab, a Licensed Product) for use in treating [*] (“[*] Trial”). After the Signature Date, Genentech and XOMA will work together to
transition the [*]Trial to Genentech or to one or more Third Parties selected and approved by Genentech. Reimbursement for Development Costs for such transition is addressed in Section 3.9. 
  
 2.2 Future Clinical Trials. During the [*] after the Effective Date,
from time to time at Genentech’s sole discretion, Genentech may propose to XOMA that XOMA conduct a Clinical Trial or provide services in support of a Clinical Trial conducted by Genentech or a Third Party and related to a Licensed Product.
XOMA will consider such proposal, and has no obligation to undertake any such Clinical Trial or to provide services in support of a Clinical Trial. If Genentech and XOMA agree to have XOMA conduct a Clinical Trial or provide services in support of a
Clinical Trial, then the Parties shall negotiate in good faith with respect to terms under which XOMA would do so. It is understood that Genentech has no obligation to offer XOMA any opportunities to conduct Clinical Trials. 
  
 2.3 Sole Decision. Genentech shall have the sole right and the sole
decision-making authority, to be exercised at its sole discretion, without consultation with XOMA or any other entity, regarding, all development, manufacturing, clinical, marketing and commercialization activities related to Licensed Products
anywhere in the world, including rights and decision-making authority regarding involvement by Third Parties. 
  

 -5- 

 ARTICLE 3: LOANS, PAYMENTS AND ROYALTIES 
  
 3.1 Finance Representatives. Each Party shall appoint a representative
to serve as a contact for payments, royalty calculations and other financial issues under this Agreement. A Party may change its financial representative, at any time, on notice to the other Party. Financial representatives are not authorized to
amend the terms of this Agreement or waive any rights on behalf of either Party. At XOMA’s request from time to time no more than once per calendar quarter, Genentech will provide to XOMA, for XOMA’s budgeting purposes only, information
regarding projected sales of Licensed Products. 
  
 3.2 Note
Agreement and Security Agreement. 
  
 (a) As consideration
for the reduction in payments and royalties to XOMA under this Agreement, as of the Effective Date, Genentech shall release XOMA Ltd. from its obligation under the Note Agreement to pay to Genentech the balance of the amount of principal loaned to
XOMA Ltd. under the Note Agreement (forty million dollars ($40,000,000)) and any interest accrued on that principal amount. XOMA Ltd.’s obligations under the Note Agreement are deemed satisfied. 
  
 (b) In connection with the foregoing release, the Security Agreement is
terminated, and Genentech shall use Commercially Reasonable and Diligent Efforts to release any claim for any security interest that it holds under or in connection with the Security Agreement. In this subsection, Commercially Reasonable and
Diligent Efforts include filing appropriate documentation with the USPTO and other governmental organizations, as appropriate. 
  
 3.3 Payments under the First Amended and Restated Agreement. Each Party is responsible for, and will continue to be responsible for, any and all
payments owing or accrued under the First Amended and Restated Agreement prior to the Effective Date of this Agreement. 
  
 (a) Royalties. Without limiting the foregoing, Genentech shall pay XOMA for all royalties, for the period prior to the Effective Date of this
Agreement, that Genentech has an obligation to pay under the First Amended and Restated Agreement. 
  
 (b) Loss Sharing. Also without limiting the foregoing, XOMA shall pay Genentech for XOMA’s share of all U.S. Commercialization Costs (as
defined in the First Amended and Restated Agreement) incurred under the First Amended and Restated Agreement for the period prior to the Effective Date of this Agreement. XOMA’s share will be calculated pursuant to the terms of the First
Amended and Restated Agreement. 
  
 (c) Payment Terms.
Within two (2) business days after the Signature Date, XOMA shall transfer to Genentech [*] dollars ($[*]), which the Parties have agreed is an estimate of XOMA’s share of the U.S. Commercialization Costs (as defined in the First Amended and
Restated Agreement) incurred during the third calendar quarter of 2004, reduced by an estimated amount of Development Costs for the first calendar quarter of 2005. The Parties will reconcile the foregoing estimates with the actual amounts on or
before ten (10) business days after the end of the first calendar quarter of 2005. For any other amounts owed by XOMA under the First Amended and Restated Agreement (including XOMA’s share of the U.S. Commercialization Costs incurred between
October 1, 2004 and December 31, 2004), Genentech may offset such amounts against royalties owed by Genentech under this Agreement. Such offset will be on a dollar-for-dollar basis until all amounts owed by XOMA under the First Amended and Restated
Agreement have been paid in full. 
  
 3.4 Royalties. This
Article 3 sets forth the only consideration due to XOMA regarding the subject matter of this Agreement. 
  

 -6- 

 (a) Initial Period Royalty. 
  
 (1) Royalty for Sales in the United States. As consideration to XOMA for the licenses and other rights granted to
Genentech under this Agreement, beginning as of the Effective Date and continuing for the first [*] from the date of the first commercial sale of a Licensed Product approved for commercial sale in the United States (i.e., [*] from November 17, 2003)
(such period, the “Initial U.S. Royalty Period”) Genentech shall make royalty payments to XOMA as follows: 
  
 (A) Genentech shall pay a royalty of [*] percent ([*]%) for the portion of Aggregate Annual Net Sales of each Licensed Product in the United States that
is less than [*] dollars (US$[*]). 
  
 (B) Genentech shall pay a
royalty of [*] percent ([*]%) for the portion of Aggregate Annual Net Sales of each Licensed Product in the United States that is equal to or greater than [*] dollars (US$[*]). 
  
 (2) Royalty for Sales in the Genentech Territory. As consideration to XOMA for the licenses and other rights granted
to Genentech under this Agreement, beginning as of the Effective Date and continuing on a country by country basis for the first [*] from the date of the first commercial sale of a Licensed Product approved for commercial sale in each such country
in the Genentech Territory (each such period an “Initial Ex-U.S. Royalty Period”), Genentech shall pay a royalty of [*] percent ([*]%) of Net Sales of each Licensed Product in such country in the Genentech Territory. Without
limiting Genentech’s obligations hereunder, it is understood that such an amount may be a pass-through royalty from one or more Ex-U.S. Genentech Partners. 
  

(b) Royalties after Initial Period. 
  
 (1) Royalty After Initial Period for Sales in the United States. As consideration to XOMA for the licenses and other rights granted to Genentech
under this Agreement, for sales inside the U.S. (i.e., sales outside the Genentech Territory) after the Initial U.S. Royalty Period and for the remainder of the Term, Genentech shall pay a royalty of either: 
  
 (A) if there is at least one FDA-approved indication for Licensed Products
and a Third Party has obtained Regulatory Approval in any such indication to market either (i) an anti-CD11a product or (ii) a Non-Anti-CD18 Anti-LFA1 Protein Product, then [*] percent ([*]%) of Net Sales in the U.S.; or 
  
 (B) if not, then [*] percent ([*]%) of Net Sales inside the U.S. (i.e.,
outside the Genentech Territory). 
  
 For purposes of this
subsection, “Non-Anti-CD18 Anti-LFA1 Protein Product” means an antibody or other protein that binds to LFA1, provided it is not an antibody that binds to CD18. 
  
 (2) No Royalty After Initial Period for Sales Outside the United States. On a country by country basis, after the
end of the applicable Initial Ex-US Royalty Period, Genentech shall not owe any payments to XOMA for sales in such country in the Genentech Territory. After the Initial Ex-U.S. Royalty Period for each country within the Genentech Territory,
Genentech shall have an exclusive, paid-up, irrevocable license under the XOMA Patents and XOMA Know-How to make, use, sell, offer for sale, have sold and import Licensed Product(s) in that country within the Genentech Territory. 
  
 (c) Third Party Royalties. Genentech is responsible for any royalties
owed to Third Parties in connection with Licensed Products. 
  
 (d) Royalty Payment Timing. Royalty payments due under this Agreement shall be made quarterly within ninety (90) days following the end of each calendar quarter for which such royalties are due. Where Genentech has the right,
pursuant to subsection 3.3(c), to offset against royalties under this Agreement amounts owed by XOMA under the First Amended and Restated Agreement, Genentech has no obligation to make payments except to the extent the royalties owed exceed the
amount Genentech has a right to offset against such royalty payments under subsection 3.3(c). 
  

 -7- 

 (e) Royalty Payment Reports. For each month during which any royalties are to be paid under this
Agreement, Genentech shall (i) provide to XOMA an initial report with a good faith estimate of Net Sales and royalties for Net Sales in the U.S. (i.e., outside the Genentech Territory), within ten (10) business days after the end of the applicable
month, and (ii) provide to XOMA an initial report with a good faith estimate of Net Sales and royalties for Net Sales inside the Genentech Territory, to the extent available to Genentech, within fifteen (15) business days after the end of the
applicable month. In addition to the initial report, each royalty payment under subsection 3.4(d) must be accompanied by a final report summarizing the Net Sales during the relevant calendar quarter on a regional basis, or such other basis as
available to Genentech. Royalties due will be promptly reconciled as necessary with reported Net Sales and Annual Aggregate Net Sales, including as a result of Genentech obtaining new or additional information from an Ex-U.S. Genentech Partner,
whether as a result of an audit of that Ex-U.S. Genentech Partner or otherwise. 
  
 (f) Audits. Genentech shall maintain its books of accounts for, and records of Net Sales for, Licensed Product for [*] after such Net Sales occur. During the [*] period for records of Net Sales, XOMA may
examine such records with respect to determining appropriate amounts of Net Sales as follows: Genentech shall permit an independent certified public accountant selected by XOMA (and reasonably acceptable to Genentech) to examine such books of
account and records kept by Genentech as may be necessary to determine the correctness of any report or payment related to such royalty payments. Any such accountant shall enter into a confidentiality agreement with both parties. Such examination
shall be made at reasonable times during regular business hours and upon at least twenty (20) business days’ prior notice. In addition, such examination may be conducted not more often than once each year and may cover only periods not
previously subject to such examination. After Genentech’s review of the accountant’s examination report and its agreement with such report, or after a final determination pursuant to Article 11, Genentech shall immediately pay all
understated royalty payments due to XOMA for Net Sales of Licensed Products by Genentech, together with interest on such amounts due from the date accrued, at the interest rate described in Section 3.4(g). XOMA shall be solely responsible for the
expenses of an examination under this Section unless there is a final determination that royalty payments under this Agreement have been, [*] in the aggregate. In that case, Genentech promptly shall reimburse XOMA for the reasonable costs of the
examination. Results of any such examination shall be provided to both Parties. Those results, along with any records or accounting information, are Confidential Information of Genentech and subject to Article 5. The foregoing clause survives
expiration or termination of the royalty obligations under this Agreement for the period of time Genentech is required to maintain its relevant books and accounts, but no more than a total of [*]. 
  
 (g) Late Payments. Any late payments under this Agreement shall bear
interest at a rate of [*] (defined as the rate published in the U.S. Federal Reserve Bulletin H.15 or any successor bulletin thereto) plus [*] percent ([*]%) per annum or the maximum rate permitted by law, whichever is less. 
  
 (h) Taxes. XOMA shall pay any and all taxes levied on account of, or
measured exclusively by, payments, including royalties, it receives under this Agreement. If laws or regulations require that taxes be withheld, Genentech shall (i) deduct those taxes from the remittable royalty, (ii) timely pay the taxes to the
proper taxing authority, and (iii) send proof of payment to XOMA within sixty (60) days following that payment. 
  
 3.5 Blocked Currency. In any country where the local currency is blocked and cannot be removed from the country, royalties shall continue to be
accrued in such country and Net Sales in such country shall continue to be reported, but such royalties will not be paid until they may be removed from the country. At such time as Genentech is able to remove such blocked currency from such country
it shall also remove and pay any royalties accrued during such blocked period on XOMA’s behalf. 
  
 3.6 Foreign Exchange. For the purpose of computing Net Sales for Licensed Products sold in a currency other than United States Dollars, such
currency shall be converted into United States Dollars in accordance with Genentech’s customary and usual translation procedures consistently applied. 
  

 -8- 

 3.7 Payments to or Reports by Affiliates. Any payment required under any provision of this
Agreement to be made to either Party or any report required to be made by any Party shall be made to or by an Affiliate of that Party if designated by that Party as the appropriate recipient or reporting entity. 
  
 3.8 Sublicensees. Any licenses or sublicenses granted by Genentech
shall include an obligation for the licensee or sublicensee to account for and report its Net Sales of Licensed Product using the same accounting standards used to determine royalties owed on Net Sales of Licensed Products and Genentech shall pay
royalties to XOMA as if the Net Sales of the sublicensee were Net Sales of Genentech. 
  
 3.9 Development Costs. 
  
 (a) Approved Budgets. Within ten (10) business days after the Signature Date, XOMA shall provide to Genentech an estimated budget of Development Costs for XOMA’s activities to transition the [*] Trial and to continue the [*]
Trial under Section 2.1. Genentech and XOMA then will work together to produce final plans for the transition of the [*] Trial, and will agree on final budgets for both the transition and the [*] Trial. Each of the final agreed budgets then is an
“Approved Budget” for purposes of this Agreement. 
  
 (b) Reimbursement. Genentech shall provide to XOMA a quarterly advance against Development Costs in an Approved Budget on or before the last day of the quarter prior to the quarter to which those advances apply; provided that the
advance for the first quarter of 2005 will be paid as set forth in Section 3.3(c). The Parties, each through its financial representative, will meet within thirty (30) days after the end of each calendar quarter to review actual Development Costs in
the just-completed calendar quarter in comparison to the just-completed quarter’s advance against Development Costs, to determine any adjustments to be applied to or refunded/paid, as applicable, to the next quarter’s advance. 

 
 (c) Overruns. Genentech has no obligation to pay XOMA for other
than Development Costs, and Development Costs are limited to no more that [*] percent ([*]%) of the amount in an Approved Budget, unless such spending is approved in advance by Genentech in writing. 
  
 (d) Reporting. XOMA shall report Development Costs in a manner
consistent with its project cost system. In general, project cost systems report actual time spent on specific projects, apply the actual labor costs, capture actual costs of specific projects and Allocable Overhead. The Parties acknowledge that the
methodologies used will be based on systems in place. 
  
 3.10
Records and Inspection. 
  
 (a) Inspection of XOMA
Records by Genentech. XOMA shall maintain complete and accurate records relevant to costs, expenses, and payments under the First Amended and Restated Agreement, and under this Agreement for periods during which Development Costs that will be
reimbursed by Genentech are being incurred. All such records must be maintained for a period of [*] from creation. During that [*] period Genentech may examine those records with respect to determining appropriate costs and expenses, as follows:
XOMA shall permit an independent certified public accountant selected by Genentech (and reasonably acceptable to XOMA) to examine any such records. Any such accountant shall enter into a confidentiality agreement with both parties. Such examination
shall be made at reasonable times during regular business hours and upon at least twenty (20) business days’ prior notice. In addition, such examination may be conducted not more often than once each year and may cover only periods not
previously subject to such examination. After XOMA’s review of the accountant’s examination report and its agreement with such report or after a final determination pursuant to Article 11, XOMA shall immediately pay to Genentech all
additional payments due to Genentech under the First Amended and Restated Agreement or this Agreement, together with interest on such amounts due from the date accrued, at the interest rate described in Section 3.4(g). Genentech shall be solely
responsible for the expenses of an examination under this Section unless there is a final determination that the expenses incurred by XOMA under the First Amended and Restated Agreement or this Agreement have been, [*] in the aggregate. In that
case, XOMA shall promptly reimburse Genentech for the reasonable costs of the examination. Results of any such examination shall be provided to both Parties. Those results, along with any records or accounting information, are Confidential
Information of XOMA and Genentech and subject to Article 5. 
  

 -9- 

 (b) Inspection of Genentech Records by XOMA. Genentech shall maintain complete and accurate
records relevant to costs, expenses, and payments under the First Amended and Restated Agreement. All such records must be maintained for a period of [*] from creation. During that [*] period XOMA may examine those records with respect to
determining appropriate costs and expenses, as follows: Genentech shall permit an independent certified public accountant selected by XOMA (and reasonably acceptable to Genentech) to examine any such records. Any such accountant shall enter into a
confidentiality agreement with both parties. Such examination shall be made at reasonable times during regular business hours and upon at least twenty (20) business days’ prior notice. In addition, such examination may be conducted not more
often than once each year and may cover only periods not previously subject to such examination. After Genentech’s review of the accountant’s examination report and its agreement with such report, or after a final determination pursuant to
Article 11, Genentech shall immediately pay to XOMA all additional payments due to XOMA under the First Amended and Restated Agreement, together with interest on such amounts due from the date accrued, at the interest rate described in Section
3.4(g). XOMA shall be solely responsible for the expenses of an examination under this Section unless there is a final determination that the expenses incurred by Genentech under the First Amended and Restated Agreement have been, [*] in the
aggregate. In that case, Genentech shall promptly reimburse XOMA for the reasonable costs of the examination. Results of any such examination shall be provided to both Parties. Those results, along with any records or accounting information, are
Confidential Information of Genentech and XOMA and subject to Article 5. 
  
 3.11 Payment Methods. Payments from Genentech to XOMA under this Article 3 will be made via a mutually agreed method consistent with Genentech’s practices, such as via wire transfer of funds to an account
in the United States designated by XOMA, via check, or via another method of payment. Payments will be in immediately available funds denominated in the currency of the United States. 
  
 ARTICLE 4: LICENSES 
  
 4.1 License to XOMA and XOMA Covenant. 
  
 (a) Genentech grants XOMA a non-exclusive license under the Genentech Patents and Genentech Know-How in the Field solely to use (but not to make, have
made, import, sell, or offer to sell) Licensed Products to perform its obligations under this Agreement regarding any Clinical Trials in the United States. Said license is royalty-free. 
  
 (b) XOMA covenants and agrees not to make, have made, sell, offer for sale or import Licensed Product anywhere in the world,
and not to use Licensed Products anywhere in the world, except in the United States pursuant to the license under subsection 4.1(a) or except as expressly authorized by Genentech. 
  
 4.2 License to Genentech Within the Field. XOMA grants to Genentech a worldwide license under the XOMA Patents and
XOMA Know-How in the Field to develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products. Such license shall be exclusive even as to XOMA in the United States and Genentech Territory (except as set forth in
subsection 4.1(a) above). 
  
 4.3 Sublicensing. Genentech
shall have an unrestricted right to grant sublicenses under this Agreement. Unless otherwise agreed, each sublicensee shall be subject to all of the obligations of Genentech hereunder applicable to that part of the territory being licensed. XOMA
shall have no right to grant sublicenses. 
  
 ARTICLE 5:
CONFIDENTIALITY 
  
 5.1 Confidentiality; Exceptions.
Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the term of this Agreement and for [*] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise
disclose or use for any purpose other than as provided for in this Agreement any Information and other information and materials furnished to it by the other 
  

 -10- 

 Party pursuant to this Agreement, including, but not limited to, financial statements and budgets (collectively,
“Confidential Information”), except to the extent that it can be established by the receiving Party that such Confidential Information: 
  
 (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party; 

 
 (b) was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the receiving Party; 
  
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
  
 (d) was disclosed to the receiving Party, other than under an obligation of
confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 
  
 (e) was subsequently developed by the receiving Party without use of the Confidential Information as demonstrated by competent written records.

  
 5.2 Authorized Use and Disclosure of Confidential
Information. 
  
 (a) XOMA may use and disclose
Genentech’s Confidential Information (i) as required to comply with a law, a governmental regulation or a court order, subject to the requirements of subsection 5.2(c), (ii) to conduct Clinical Trials of Licensed Products; provided that
disclosure of Genentech’s Confidential Information to a Third Party must be under a binder of confidentiality containing provisions substantially as protective as those of this Article 5 or (iii) to prosecute or defend litigation, after such
disclosure has been approved by Genentech. 
  
 (b) Genentech may
use and disclose XOMA’s Confidential Information (i) as required to comply with a law, a governmental regulation or a court order, subject to the requirements of subsection 5.2(c), (ii) to conduct preclinical or Clinical Trials of Licensed
Products, (iii) to file and prosecute Patent applications, or (iv) to prosecute or defend litigation. Genentech also may disclose XOMA’s Confidential Information, under a binder of confidentiality containing provisions substantially as
protective as those of this Article 5, (x) to its licensors of intellectual property and other rights related to Licensed Products, or (y) to consultants, potential and actual sublicensees and other Third Parties, for any purpose provided for in
this Agreement and/or in connection with the development and commercialization of Licensed Products. 
  
 (c) If a Party is required by law or regulation to make any disclosure of the other Party’s Confidential Information it will, except where
impracticable for necessary disclosures, for example in the event of medical emergency, give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications, will
use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed. 
  
 (d) Nothing in this Article 5 shall restrict Genentech from using for any purpose any Information developed by it during the course of the activities
under this Agreement. 
  
 5.3 Survival. This Article 5
shall survive the termination or expiration of this Agreement for a period of [*]. 
  
 5.4 Termination of Prior Agreement. This Article 5 supersedes Article 11 of the Original Agreement, Article 12 of the First Amended and Restated Agreement, and the Confidentiality Agreements between the Parties
dated October 11, 1995, one of which was last signed on October 20, 1995 and one of which was last signed on January 11, 1996 and both of which were amended on April 11, 1996, except that the Research Scientists, as defined in the Oxford Agreement,
shall continue to be third party beneficiaries under this Agreement to the extent 
  

 -11- 

 such previous Confidentiality Agreement is superseded. All Information exchanged between the Parties under the above
referenced agreements shall be deemed Confidential Information and shall be subject to the terms of this Article 5 as of the Effective Date. 
  
 5.5 Press Releases; Use of Names. 
  
 (a) Except as expressly set forth in this Agreement, no right, express or implied, is granted by this Agreement to use in any manner the name
“XOMA,” “Genentech” or any other trade name or trademark of the other Party or its Affiliates in connection with the performance of this Agreement. 
  
 (b) Neither XOMA nor Genentech will issue any press release or make any other public announcement concerning the existence
of this Agreement, the relationship between the Parties, the subject matter of this Agreement, the status of any Licensed Products or any Clinical Trials for those Licensed Products, except as follows: (i) as part of an initial press release
mutually agreed upon by the Parties, (ii) to the extent permitted by prior consent of the other Party, (iii) to the extent that disclosure of the information contained in such press release or public announcement has been previously approved by the
other Party in substantially the same form, (iv) to attorneys, consultants and accountants retained to represent a Party in connection with the transactions contemplated hereby, subject to obligations of confidentiality of such attorneys,
consultants or accountants (which must be the subject of a written agreement in the case of consultants), and (v) as required to be disclosed to comply with applicable law or regulation, including pursuant to the disclosure requirements of the
Securities and Exchange Commission or similar body. Each Party shall obtain its own legal advice regarding compliance with securities laws. 
  
 (c) Requests for approval of any press release or other public announcement covered under (b)(ii) above must be submitted no less than [*] prior to the
proposed date of such press release or public announcement; provided that each Party’s approval may be delayed until the occurrence of the event triggering such press release or public announcement. Proposed filings and other disclosures
covered under (b)(v) above must be submitted no less than [*] prior to the date of the proposed filing, and the filing Party must seek confidential treatment of the Agreement if filed as an Exhibit. Notwithstanding the foregoing, if the filing Party
is required by law to make disclosure within fewer than [*] after an event, then the filing Party will submit proposed filings and disclosures with as much advance notice as reasonably possible, and the reviewing Party will use reasonable efforts to
review that filing within the period of time indicated by the filing Party. Any review will be for purposes of notice and accuracy, but will not be considered legal advice regarding compliance with securities laws. 
  
 (d) During the first [*] after the Effective Date, Genentech will use
Commercially Reasonable and Diligent Efforts to make advance disclosure to XOMA of those portions of any press release, publicity or public disclosure or statement that mention XOMA in the context of Licensed Products or Genentech’s
relationship to XOMA under this Agreement. Subject to this subsection, Genentech’s public disclosures of new Information not previously released and all Genentech press releases related to this Agreement or to any Licensed Product(s) are at
Genentech’s sole discretion, and Genentech has sole authority as to the content and timing of such disclosures. 
  
 ARTICLE 6: 
 OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

  
 6.1 Ownership of Intellectual Property. XOMA shall
own all inventions made under this Agreement solely by its employees (“XOMA Inventions”). Genentech shall own all inventions made under this Agreement solely by its employees (“Genentech Inventions”). All inventions
made under this Agreement jointly by employees of XOMA and Genentech (“Joint Inventions”) will be owned jointly by XOMA and Genentech and each Party shall retain full ownership under any Patents resulting therefrom (“Joint
Patents”), with full ownership rights in any field and the right to sublicense without the consent of the other Party, without accounting. The laws of the United States with respect to inventorship shall apply in all jurisdictions giving
force and effect to this Agreement. 
  
 6.2 Disclosure of
Patentable Inventions. XOMA shall provide to Genentech any invention disclosure that discloses an invention that relates to a Licensed Product. Such invention disclosures shall be provided to Genentech within thirty (30) days after XOMA
determines that an invention has been made. 
  

 -12- 

 6.3 Patent Filings. 
  
 (a) Initial Responsibility. Genentech, at its sole discretion, responsibility and expense, shall file, prosecute and
maintain Patents in the United States to cover Genentech Inventions, Joint Inventions and XOMA Inventions relating to any Licensed Product. The determination of the countries in the Genentech Territory in which to file any patent applications on
Genentech Inventions, Joint Inventions and XOMA Inventions relating to any Licensed Product shall be made by Genentech, and Genentech shall be responsible for such filings in such countries. Genentech shall have the right, at its expense, to direct
and control all material actions relating to the prosecution or maintenance of Genentech Patents, Joint Patents and XOMA Patents in the United States and Genentech Territory, including without limitation, interferences, oppositions, appeals and
revocation proceedings. 
  
 (b) XOMA Patents and Joint
Patents. If Genentech elects not to file a XOMA Patent or a Joint Patent, it shall so inform XOMA. XOMA may then file, prosecute and maintain any such XOMA Patent or Joint Patent at its sole responsibility and expense. The Party responsible for
filing such a XOMA Patent or Joint Patent will be termed the “filing Party.” The filing Party shall keep the other Party reasonably apprised of the status of each XOMA Patent and Joint Patent and shall seek the advice of the other Party
with respect to patent strategy and draft applications and shall give reasonable consideration to any suggestions or recommendations of the other Party concerning the preparation, filing, prosecution, maintenance and defense thereof. The Parties
shall cooperate reasonably in the prosecution of all XOMA Patents and Joint Patents and shall share all material information relating thereto promptly after receipt of such information. If, during the term of this Agreement, Genentech intends to
allow any XOMA Patent or Joint Patent relating to a Licensed Product to lapse or become abandoned without having first filed a substitute, Genentech shall make reasonable efforts to notify XOMA of such intention at least sixty (60) days prior to the
date upon which such XOMA Patent or Joint Patent shall lapse or become abandoned, and XOMA shall thereupon have the right, but not the obligation, to assume responsibility for the prosecution, maintenance and defense thereof at its sole expense.

  
 (c) Initial Filings if Made Outside of the United
States. The Parties agree to use reasonable efforts to ensure that any Patent that relates to the subject matter of this Agreement and is filed outside of the United States prior to a U.S. filing will be in a form sufficient to establish the
date of original filing as a priority date for the purposes of a subsequent U.S. filing. 
  
 6.4 Enforcement Rights. 
  
 (a) Enforcement. Genentech shall have the right, but not the obligation, to institute, prosecute and control at its own expense any action or proceeding with respect to infringement of any of the Genentech Patents, Joint Patents and
XOMA Patents by counsel of its own choice. XOMA shall have the right, at its own expense, to be represented in any action for infringement of XOMA Patents or Joint Patents by counsel of its own choice. If Genentech elects not to institute such
action or proceeding with respect to any XOMA Patent, XOMA shall have the right at its sole expense to institute such action or proceeding, and Genentech shall have the right, at its own expense, to be represented in any action by counsel of its
choice. In the event of an infringement of a Joint Patent, the Parties shall decide the best way to proceed. If one Party brings any such action or proceeding, the other Party agrees to be joined as a party plaintiff if necessary to prosecute the
action or proceeding and to give the first Party reasonable assistance and authority to file and prosecute the suit. Any damages or other monetary awards recovered pursuant to this Section 6.4 shall be allocated first to the costs and expenses of
the Party bringing suit, then to the costs and expenses, if any, of the other Party. Any amounts remaining shall be retained by the Party bringing suit. 
  
 (b) Settlement with a Third Party. The Party that controls the prosecution of a given claim with respect to a Licensed Product shall also have the
right to control settlement of such claim; provided, however, that if one Party controls, no settlement shall be entered into without the written consent of the other Party if such settlement would materially and adversely affect the interests of
such other Party. If there is no agreement between the Parties, then the dispute will be resolved pursuant to Article 11. 
  

 -13- 

 6.5 Infringement Defense. If a Third Party asserts that a Patent or other right owned by it is
infringed by any Licensed Product, Genentech will be solely responsible for deciding how and whether to defend against any such assertions at its cost and expense. XOMA shall have the right, at its own expense, to be represented in any such action
by counsel of its choice. No settlement of such an action shall be entered into by Genentech without XOMA’s written consent if such settlement would materially and adversely affect XOMA’s interests. 
  
 ARTICLE 7: REPRESENTATIONS AND WARRANTIES 
  
 Representations and Warranties. Each of the Parties hereby represents and
warrants as follows: 
  
 (a) This Agreement is a legal and valid
obligation binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it
is a party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 
  
 (b) XOMA has not granted, and during the term of this Agreement will not grant, any right to any Third Party relating to its
respective Patents and know-how related to the use of Licensed Products in the Field, if that right would conflict with the rights granted to Genentech. 
  
 (c) Such Party has the right to grant the licenses it has granted herein. 
  
 7.2 Performance by Affiliates. The Parties recognize that each may perform some or all of its obligations under this
Agreement through Affiliates; provided, however, that each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such
performance. 
  
 ARTICLE 8: INFORMATION AND REPORTS

  
 8.1 Contribution of Information. XOMA shall
disclose to Genentech all preclinical, clinical, regulatory, commercial and other information that is obviously useful to the development and commercialization of Licensed Products and that is either (i) known by XOMA as of the Effective Date, or
(ii) becomes known by XOMA as a result of activities related to a Clinical Trial (“Relevant Information”). Within [*] after the Signature Date, XOMA shall provide to Genentech a list of all such Relevant Information then existing,
and, promptly upon written request by Genentech thereafter, transfer to Genentech a copy of any such requested Relevant Information, including (if so requested) a copy of XOMA’s own database of data from any and all Clinical Trials of a
Licensed Product for which XOMA was responsible. XOMA shall transfer to Genentech copies of additional Relevant Information at the end of any Clinical Trial and upon request by Genentech. Unless otherwise agreed, the Parties will use the same
procedure regarding transfer of Relevant Information as had been used in the most recent project. However, at the option of Genentech, Relevant Information shall be provided in a computer readable format by XOMA, to the extent available, and XOMA
shall also assist in the transfer to Genentech and the validation of data within Relevant Information. 
  
 8.2 Compliance with Privacy Laws. Notwithstanding Section 8.1, XOMA has no obligation to make disclosures prohibited by law or contract. XOMA shall
use Commercially Reasonable and Diligent Efforts to obtain all necessary consents required for disclosure of the data and reports which XOMA is required to provide to Genentech pursuant to this Agreement. In the event that any such consent can not
be obtained, XOMA shall provide to Genentech data and documentation that have been redacted to make disclosure lawful. 
  
 8.3 Complaints. If XOMA receives any complaints with respect to any Licensed Product, then XOMA shall notify Genentech, providing sufficient
detail, within [*] after the event, and in any event in sufficient time to allow Genentech to comply with any and all regulatory requirements imposed upon it in any country. 
  

 -14- 

 8.4 IND’s for Licensed Products. IND’s for Clinical Trials conducted under this
Agreement, along with IND’s for any Licensed Product, will be held by Genentech and not XOMA. To the extent XOMA currently holds any IND’s for Clinical Trials that are to be conducted by XOMA, it shall continue to hold those IND’s
until the completion of such Clinical Trial, after which XOMA will transfer such IND to Genentech and Genentech will hold such IND. To the extent XOMA currently holds any IND’s related to the Licensed Product or to completed Clinical Trials,
XOMA shall work with Genentech in good faith to transfer those IND’s to Genentech. 
  
 8.5 Adverse Drug Events. The Parties recognize that the holder of a Drug Approval Application may be required to submit information and file reports to various governmental agencies on compounds under clinical
investigation, compounds proposed for marketing or marketed drugs. Such information must be submitted at the time of initial filing for investigational use in humans and at the time of a request for market approval of a new drug. In addition,
supplemental information must be provided on compounds at periodic intervals and adverse drug experiences must be reported at more frequent intervals depending on the severity of the experience. Consequently, XOMA shall provide Genentech with the
following information and reports of which it has knowledge: 
  
 (a) for initial and/or periodic submission to government agencies, significant information relating to Licensed Product from preclinical laboratory, animal toxicology and pharmacology studies, as well as adverse drug experience reports from
Clinical Trials and registries with a Licensed Product, to the extent XOMA has such information in its possession or control; 
  
 (b) all adverse drug event information for any Licensed Product of which XOMA is or becomes aware; 
  
 (c) in connection with a Licensed Product in a Clinical Trial conducted for
approval by a regulatory agency, reports of any Unexpected Adverse Event (defined below) or Serious Adverse Event (defined below), within [*] of the initial receipt of a report of such event or sooner if required for Genentech to comply with
regulatory requirements; and 
  
 (d) for a Licensed Product that
has received Regulatory Approval, a report of any adverse event for that Licensed Product that is a Serious Adverse Event and or an Unexpected Adverse Event, within [*] of the initial receipt of a report or sooner if required for Genentech to comply
with regulatory requirements. 
  
 “Serious Adverse Event” is any
event that suggests a significant hazard, contraindication, side effect or precaution, or any event that is fatal or life threatening, is permanently disabling, requires or prolongs inpatient hospitalization or is a congenital anomaly, cancer or
overdose. An “Unexpected Adverse Event” is any adverse event not identified in nature, specificity, severity or frequency in the current investigator brochure or the U.S. labeling for the Licensed Product. 
  
 ARTICLE 9: TERM AND TERMINATION 
  
 9.1 Term. This Agreement commences as of the Effective Date and
continues until such time as no Licensed Product is any longer being developed or commercialized anywhere in the world by Genentech, any Ex-U.S. Genentech Partner, or any sublicensees of the foregoing (such period, the “Term”).

  
 9.2 No Termination for Material Breach. Upon the
material failure of either Party to comply with any of its material obligations under this Agreement, all remedies in law and in equity shall be available to the non-breaching Party, except that the non-breaching Party may not terminate this
Agreement. 
  
 9.3 Consequences of Termination or
Expiration. 
  
 (a) Licenses. The licenses granted to
Genentech under this Agreement survive any expiration or termination of this Agreement. Royalty obligations continue in accordance with the terms of Article 3. 
  

 -15- 

 (b) Ownership of Certain Materials. As between the Parties, Genentech will own (a) any
investigational new drug applications for any Clinical Trials related to Licensed Products, and (b) any data provided by XOMA to Genentech, including data required to be provided under Article 8. 
  
 (c) Surviving Rights. As of the end of the Term, all obligations and
rights of the Parties under this Agreement terminate, except those obligations and rights under the following Articles, Sections and subsections, which continue perpetually or in accordance with their terms: Article 3 (Loans, Payments and Royalties)
(for the periods indicated), Section 4.2 (License to Genentech), Section 4.3 (Sublicensing), Article 5 (Confidentiality) (for the period indicated), Section 6.1 (Ownership of Intellectual Property), Article 7 (Representations and Warranties),
Section 9.3 (Consequences of Termination or Expiration), Section 9.4 (Bankruptcy), Section 10.1 (Indemnification), Section 10.2 (Limitation of Liability), Article 11 (Dispute Resolution), and Article 12 (Miscellaneous). 
  
 (d) No Prejudice. Termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any payments which shall have accrued to the benefit of either Party prior to such termination, relinquishment or expiration, including damages arising from any breach hereunder. 
  
 (e) Bankruptcy. Either Party may, in addition to any other remedies
available to it by law or in equity, terminate this Agreement, in whole or in part as the terminating Party may determine, by written notice to the other Party, in the event the other Party shall have become bankrupt, shall have made an assignment
for the benefit of its creditors or there shall have been appointed a trustee or receiver of the other Party or for all or a substantial part of its property or any case or proceeding shall have been commenced or other action taken by or against the
other Party in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up, arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or other similar act or law of any
jurisdiction now or hereafter in effect and any such event shall have continued for sixty (60) days undismissed, unbonded and undischarged. All rights and licenses granted under this Agreement by one Party to the other Party are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(56) of the Bankruptcy Code. The Parties agree that the licensing Party under this Agreement
shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code in the event of a bankruptcy by the other Party. The Parties further agree that in the event of the commencement of a bankruptcy proceeding by or against
one Party under the Bankruptcy Code, the other Party shall be entitled to complete access to any such intellectual property pertaining to the rights granted in the licenses hereunder of the Party by or against whom a bankruptcy proceeding has been
commenced and all embodiments of such intellectual property. 
  
 ARTICLE 10: INDEMNIFICATION, LIMITATION OF LIABILITY, INSURANCE 
  
 10.1 Indemnification. 
  
 (a) Genentech hereby agrees to save, defend and hold XOMA and its agents and employees harmless from and against any and all losses, damages, liabilities, settlements, suits, claims, actions, demands, penalties, fines, costs and expenses
(including reasonable attorney’s fees and expenses) (collectively the “Losses”) resulting directly from the manufacture, use, handling, storage, sale or other disposition of Licensed Products sold or used by Genentech, its
Affiliates, agents or sublicensees, except to the extent such Losses result from the negligence or willful misconduct of XOMA, and also except for any Losses resulting directly from XOMA’s use of Genentech’s processes or technology which
XOMA or its agents have modified without Genentech’s prior written consent. 
  
 (b) In the event that XOMA is seeking indemnification under subsection 10.1(a), it shall inform Genentech of a claim as soon as reasonably practicable after it receives notice of the claim, shall permit Genentech to
assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as reasonably requested (at the expense of Genentech) in the defense of the claim. 

 
 (c) XOMA hereby agrees to save, defend and hold Genentech and its agents
and employees harmless from and against any and all Losses resulting directly from XOMA’s activities under this Agreement, except 
  

 -16- 

 to the extent such Losses result from the negligence or willful misconduct of Genentech, and also except for any Losses
resulting directly from Genentech’s use of any of XOMA’s processes or technology which Genentech or its agents have modified without XOMA’s prior written consent. 
  
 (d) In the event that Genentech is seeking indemnification under subsection 10.1(c), it shall inform XOMA of a claim as soon
as reasonably practicable after it receives notice of the claim, shall permit XOMA to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as
reasonably requested (at the expense of XOMA) in the defense of the claim. 
  
 10.2 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY OF THE OTHER PARTY’S AFFILIATES FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES (INCLUDING
LOST PROFITS) SUFFERED BY THE OTHER PARTY OR ITS AFFILIATES IN RELATION TO ANY SUBJECT MATTER OF THIS AGREEMENT (INCLUDING WITHOUT LIMITATION WITH RESPECT TO PERFORMANCE OF THIS AGREEMENT OR LACK THEREOF) UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, EVEN IF SUCH PARTY OR ITS AFFILIATES HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS, DAMAGE, OR COST, EXCEPT TO THE EXTENT IT MAY BE REQUIRED TO INDEMNIFY THE OTHER PARTYAS EXPRESSLY PROVIDED HEREIN.

  
 10.3 Insurance Matters. 
  
 (a) Each Party shall maintain, on an ongoing basis, Commercial General
Liability (“CGL”) insurance, including contractual liability, in the minimum amount of [*] dollars ($[*]) per occurrence and [*] dollars ($[*]) annual aggregate combined single limit for bodily injury and property damage liability.
Each Party shall maintain on an ongoing basis Products Liability (“PL”) insurance (including contractual liability) in the amount of at least [*] dollars ($[*]) per occurrence and annual aggregate combined single limit for bodily
injury and property damage liability. 
  
 (b) Upon request of the
other Party, each Party shall provide to the other Party certificates evidencing all such required coverage hereunder; each such certificate shall set forth the period of insurance and the limits of coverage and shall be provided each year. CGL and
PL insurance policies shall be an occurrence form, but if only a claims-made form is available, then it may be in a claims-made form, subject to compliance with all of the terms of this Section 10.3. Each of the above insurance policies shall be
primary insurance with respect to each Party’s own participation under this Agreement. The aggregate deductibles under such CGL and PL insurance policies shall be reasonably satisfactory to the other Party. At the request of either Party, the
Parties agree to review and discuss the requirements under this Section 10.3. 
  
 (c) Each Party shall procure and maintain at its own cost clinical trial insurance with minimum limits as required by law and/or country, for the duration of any Clinical Trials conducted under this Agreement.

  
 (d) All of the above insurance coverage shall be maintained
with an insurance company or companies having an A.M. Best rating of X-VII or better. 
  
 ARTICLE 11: DISPUTE RESOLUTION 
  
 11.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the term of this Agreement which relate to either Party’s rights and/or obligations hereunder. It is the objective of
the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the
procedures set forth in this Article 11 if and when any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity hereof (“Article 11 Disputes”). Article 11 Disputes first
will be referred to a Vice President or Senior Vice President of Genentech and the Chief 
  

 -17- 

 Executive Officer or a Vice President of XOMA. If after sixty (60) days the dispute remains unresolved, the Parties agree
to refer the matter to mediation pursuant to Section 11.2. If after forty-five (45) days the matter cannot be resolved by mediation, the Parties agree to submit to arbitration pursuant to Section 11.3. 
  
 11.2 Mediation. For Article 11 Disputes, except (a) disputes relating
to intellectual property owned in whole or in part by XOMA or Genentech, or (b) claims for equitable relief, the Parties shall try in good faith to resolve such dispute by mediation administered by the American Arbitration Association in accordance
with its Commercial Mediation Rules. The mediation proceeding shall be conducted at the location of the Party not originally requesting resolution of the dispute. The Parties agree that they shall share equally the cost of the mediation filing and
hearing fees, and the cost of the mediator. Each Party must bear its own attorney’s fees and associated costs and expenses. 
  
 11.3 Arbitration. For Article 11 Disputes not resolved pursuant to Section 11.1 or Section 11.2 within the time periods provided, except (a)
disputes relating to intellectual property owned in whole or in part by XOMA or Genentech, or (b) claims for equitable relief, upon ten (10) days written notice, either Party may initiate arbitration by giving notice to that effect to the other
Party and by filing the notice with the American Arbitration Association in accordance with its Commercial Arbitration Rules. Such dispute shall then be settled by arbitration in California in accordance with the Commercial Arbitration Rules of the
American Arbitration Association or other rules agreed to by the Parties, by a panel of three (3) neutral arbitrators, who shall be selected by the Parties using the procedures for arbitrator selection of the American Arbitration Association.

  
 (a) The Parties acknowledge that this Agreement evidences a
transaction involving interstate commerce. Insofar as it applies, the United States Arbitration Act shall govern the interpretation of, enforcement of, and proceedings pursuant to the arbitration clause in this Agreement. Except insofar as the
United States Arbitration Act applies to such matters, the agreement to arbitrate set forth in this Section 11.3 shall be construed, and the legal relations among the Parties shall be determined in accordance with, the substantive laws of
California. 
  
 (b) The panel shall render its decision and award,
including a statement of reasons upon which such award is based, within thirty (30) days after the arbitration hearing. The decision of the panel shall be determined by majority vote among the arbitrators, shall be in writing and shall be binding
upon the Parties, final and non-appealable. Judgment upon the award rendered by the panel may be entered in any court having jurisdiction thereof in accordance with Section 11.4. 
  
 (c) Except as provided under the United States Arbitration Act and with respect to the infringement, validity and/or
enforceability of patent rights, no action at law or in equity based upon any dispute that is subject to arbitration under this Section 11.3 shall be instituted. 
  
 (d) All expenses of any arbitration pursuant to this Section 11.3, including fees and expenses of the Parties’
attorneys, fees and expenses of the arbitrators, and fees and expenses of any witness or the cost of any proof produced at the request of the arbitrators, shall be paid by the non-prevailing Party. 
  
 (e) For the purposes of Section 11.2 and Section 11.3, the Parties agree to
accept the jurisdiction of the federal courts located in the Northern District of California for the purposes of enforcing the agreements reflected in this Section 11.2 and 11.3. 
  
 11.4 Jurisdiction and Governing Law. For any disputes not subject to arbitration or mediation above, California law
(excluding conflict of laws principles) governs and the Parties accept the jurisdiction of the state courts geographically located in the Northern District of California or the federal courts within the Northern District of California. 

 
 11.5 Determination of Patents and Other Intellectual Property. Any
dispute relating to the determination of validity of a Party’s Patents or other issues relating solely to a Party’s intellectual property shall be submitted exclusively to the federal courts located in the Northern District of California,
San Francisco Division, and the Parties hereby consent to the jurisdiction and venue of such court. 
  

 -18- 

 ARTICLE 12: MISCELLANEOUS 
  
 12.1 Assignment. 
  
 (a) XOMA may freely assign its rights to receive payment from Genentech under this Agreement, but shall provide notice to Genentech of such assignment
immediately upon such assignment. With respect to XOMA’s other rights and obligations hereunder, XOMA shall not assign or delegate such obligations (including by operation of law, in connection with a change of control, merger or otherwise)
without prior written consent of Genentech. Any purported or attempted assignment in violation of the foregoing is void, and will be considered a material breach of this Agreement. 
  
 (b) Genentech may assign all of its rights and obligations under this Agreement (a) freely in connection with a merger or
reorganization or the sale of all or substantially all of its assets to which this Agreement relates, or (b) with the prior written consent of XOMA. This Agreement shall survive any such merger or reorganization of Genentech with or into, or such
sale of assets to, another party and no consent (except as otherwise set forth above) for such merger, reorganization or sale shall be required hereunder. 
  
 (c) This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance
with this Agreement shall be void. 
  
 12.2 Retained
Rights. Nothing in this Agreement shall limit in any respect the right of either Party to conduct research and development with respect to and market products outside the Field using such Party’s technology. 
  
 12.3 Force Majeure. Neither Party shall lose any rights hereunder or
be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by government action, war, terrorism, fire, explosion, flood, earthquake, strike, lockout, embargo, act of
God, or any other cause beyond the control of the defaulting Party; provided that the Party claiming force majeure has exerted all Commercially Reasonable and Diligent Efforts to avoid or remedy such force majeure; provided, however, that in no
event shall a Party be required to settle any labor dispute or disturbance. 
  
 12.4 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement. 
  
 12.5 Notices. All notices
hereunder shall be in writing and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier
service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided that notices of a change of address shall be effective only upon receipt thereof). 
  
 If to XOMA, 
  
 addressed to: XOMA (US) LLC 
 2910 7th Street 
 Berkeley, California 94710 
 Attention: Company Secretary 
 Telephone:
(510) 204-7200 
 Telecopy: (510) 649-7571 
  
 with a copy to: Chief Financial Officer 
  

 -19- 

 If to Genentech, 
  
 addressed to: GENENTECH, INC. 
 1 DNA Way 
 South San Francisco, CA 94080 
 Attention: Corporate Secretary 
 Telephone:
(650) 225-1000 
 Telecopy: (650) 952-9881 
  
 with a copy to the Vice President of Business Development 
 Telecopy: (650) 225-3009 
  
 12.6
Waiver. Except as specifically provided for herein, the waiver from time to time by either of the Parties of any of its rights or its failure to exercise any remedy shall not operate or be construed as a continuing waiver of same or of any
other of such Party’s rights or remedies provided in this Agreement. 
  
 12.7 Severability. If any term, covenant or condition of this Agreement or the application thereof to any Party or circumstance shall, to any extent, be held to be invalid or unenforceable, then (i) the
remainder of this Agreement, or the application of such term, covenant or condition to Parties or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of
this Agreement shall be valid and be enforced to the fullest extent permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably
acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 

 
 12.8 Ambiguities. Ambiguities, if any, in this Agreement shall not
be construed against either Party, irrespective of which Party may be deemed to have authorized the ambiguous provision. 
  
 12.9 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
  
 12.10
Previous Activities. [*]. 
  
 12.11 Entire
Agreement. This Agreement, including all Exhibits attached hereto, which are hereby incorporated herein by reference, together with the Common Stock and Convertible Note Purchase Agreement dated as of April 22, 1996, as amended, sets forth all
the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and, as of the Effective Date, supersedes all prior agreements and understandings between the Parties, including but not
limited to the First Amended and Restated Agreement, the Note Agreement and the Security Agreement, except for the remaining obligations described in this Agreement. There are no covenants, promises, agreements, warranties, representations,
conditions or understandings, either oral or written, between the Parties regarding the subject matter herein other than as set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon
the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 
  

 -20- 

 IN WITNESS WHEREOF, the Parties have executed this Second Amended and Restated Collaboration
Agreement in duplicate originals by their proper officers as of the Effective Date. 
  

							
	XOMA (US) LLC	 	GENETECH, INC.
				
	By:	 	 /s/ PETER B. DAVIS

	 	By:	 	 /s/ LOUIS J. LAVIGNE, JR.

	 	 	Peter B. Davis	 	 	 	Louis J. Lavigne, Jr.
				
	Title:	 	Vice President, Finance and Chief	 	Title:	 	Executive Vice President and Chief
	 	 	Financial Officer	 	 	 	Financial Officer

  
 With respect to the Recitals and
Section 3.2 only: 
 XOMA Ltd. 
  

			
	By:	 	 /s/ CHRISTOPHER J. MARGOLIN

	 	 	Christopher J. Margolin
		
	Title:	 	Vice President, General Counsel and Secretary

  

 -21- 

 Exhibit A 
 Anti-CD11a 
  
 Anti-CD11a Antibody Full Length Amino Acid Sequences 
  
 [*] 

 EXHIBIT B 
  

The “Itakura/Riggs Patents” shall mean the following U.S. patents and any and all divisionals, continuations, continuations-in-part of any
application from which these U.S patents claim priority, including reissues, reexaminations or extensions of these patents and foreign counterparts and supplementary protection certificates of the foregoing: 
  
 U.S. 4,356,270 
 U.S. 4,366,246 
 U.S. 4,425,437 
 U.S. 4,431,739 
 U.S. 4,563,424 
 U.S. 4,571,421

 U.S. 4,704,362 
 U.S. 4,812,554 
 U.S. 5,221,619 
 U.S. 5,420,020 
 U.S. 5,583,013 
  
 The “Cabilly Coexpression Patents” shall mean U.S. Patent No. 6,331,415 issued December 18, 2001, and any and all patents issuing from divisionals, continuations, or continuations-in-part of any application
from which U.S. Patent No. 6,331,415 claims priority, including reissues, reexaminations or extensions of these patents and foreign counterparts and supplementary protection certificates of the foregoing. Cabilly Coexpression Patents shall not
include Cabilly Chimera Patents identified below. 
  
 “Cabilly Chimera Patents” shall mean (i) U.S. Patent No. 4,816,567, issued March 28, 1989, and (ii) any claims directed to chimeric antibodies which claims are found in any patent(s) issuing from divisionals, continuations, or
continuations-in-part of any application from which U.S. Patent No. 4,816,567 claims priority, or (iii) which claims are found in any patents that are reissues, reexaminations, extensions, or foreign counterparts of any of the foregoing (i) or (ii).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]